AMT-116 in Combination With AK112 in Patients With Lung Cancer

The purpose of this study is to evaluate the safety and efficacy of AMT-116 in combination with Ivonescimab (AK112) in patients with advanced non-small cell lung cancer (NSCLC). The study is divided into two parts: the part I is dose escalation and the Part Ⅱ for expansion.

Trial Details

NCT ID
NCT07590531
Phase
PHASE1 / PHASE2
Sponsor
Multitude Therapeutics Inc.
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • AMT-116
  • AK112
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Hangzhou, Zhejiang, China|30.29365,120.16142

Key Eligibility Criteria

  • Willing and able to provide written informed consent for this trial.
  • At the time of screening, aged ≥18 years and ≤75 years.
  • Histologically or cytologically confirmed locally advanced (Stage IIIB/III C) or metastatic (Stage IV) NSCLC that is not amenable to complete surgi…
  • Stage Ib: Locally advanced/metastatic NSCLC; both subjects who have previously received systemic therapy and those who have not may be enrolled;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →